Which big pharma firms are best at digital?New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital Share XWhich big pharma firms are best at digital?https://pharmaphorum.com/views-analysis-digital/which-big-pharma-firms-are-best-at-digital/
Innovative contracting in Europe: a Trojan Horse?By Mary Iyiola & Agnieszka Janska, with additional consultation by Smita Sealey & Barry Farrimond In a recent Share XInnovative contracting in Europe: a Trojan Horse?https://pharmaphorum.com/views-analysis-market-access/innovative-contracting-in-europe-a-trojan-horse-2/
Should you lie to your granny?When it comes to healthcare there are different opinions about patient care east and west, and as market Share XShould you lie to your granny?https://pharmaphorum.com/views-and-analysis/should-you-lie-to-your-granny-healthcare/
Navigating emerging markets – opportunities and challenges for pharmaThe pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of Share XNavigating emerging markets – opportunities and challenges for pharmahttps://pharmaphorum.com/views-analysis-market-access/navigating-emerging-markets-opportunities-and-challenges-for-pharma/
Humanising healthcare through technologyAn early exposure to computer science by way of the Commodore 64, combined with subsequent medical studies, set Share XHumanising healthcare through technologyhttps://deep-dive.pharmaphorum.com/magazine/sales-and-marketing-2019/humanising-healthcare-through-technology/
Comms from the ground upDavid Hunt’s career has taken him from painting Havas Lynx Group’s offices to running the agency, and now Share XComms from the ground uphttps://deep-dive.pharmaphorum.com/magazine/sales-and-marketing-2019/comms-from-the-ground-up-david-hunt-havas/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Bridging the gap between industry and charities: Enabling PPI in researchPublic and patient involvement (PPI) in clinical research is the new normal, but bridging the gap between how Share XBridging the gap between industry and charities: Enabling PPI in researchhttps://pharmaphorum.com/views-analysis-patients/bridging-the-gap-between-industry-and-charities-enabling-ppi-in-research/
A new breed of pharma manufacturingOver the last few years the effect of Brexit’s political instability on our industry has been inescapable as Share XA new breed of pharma manufacturinghttps://pharmaphorum.com/r-d/views-analysis-r-d/a-new-breed-of-pharma-manufacturing/
